One of the primary responsibilities of a National Cancer Institute (NCI)-designated Comprehensive Cancer Center is to conduct high-impact research that will advance the prevention and treatment of cancer. Continuously funded by the NCI through a Cancer Center Support Grant (P30CA072720), Rutgers Cancer Institute upholds its NCI designation with significant engagement in clinical, basic, and population-based cancer research. Our researchers conduct matrix-style investigations that bridge these scientific areas together into one coordinated effort in the fight against cancer.
Rutgers Cancer Institute attracts investigators from a wide range of scientific disciplines. Based on the research strengths of our members, our research programs are organized into four programs that foster interdisciplinary coordination and collaboration.
Cancer Metabolism and Immunology (CMI)
Program aims are to identify new approaches to improve cancer treatment by studying changes in tumor cell metabolism, growth, proliferation, survival, and tumor-host interaction.
Program Leaders: Wenwei Hu, PhD, Kyle Payne, PhD and Christian Hinrichs, MD
Genomic Instability and Cancer Genetics (GICG)
Program aims are to identify biomarkers and therapeutic targets by studying and defining tumor cell genomes, repair mechanisms, and gene expression.
Program Leaders: Chang S. Chan, PhD, Cristina Montagna, PhD and Matthew Deek, MD
Cancer Pharmacology (CP)
Program aims are to discover and develop more effective cancer treatments.
Program Leaders: X. F. Steven Zheng, PhD, Stephen K. Burley, MD, DPhil and Peter Cole, MD
Cancer Prevention and Control (CPC)
Programs aims are to reduce cancer burden in New Jersey and beyond by examining and improving clinical and public health practice and policies across the cancer control continuum.
Program Leaders: Carolyn J. Heckman, PhD and Elisa V. Bandera, MD, PhD
Calendar of Program Meetings & Events for Cancer Institute Members